Gilead Sciences, Inc. $GILD Shares Bought by Swedbank AB

Key Points

• Swedbank AB increased its stake in Gilead Sciences, Inc. by 0.8% during the first quarter, owning approximately 2.12 million shares valued at $237.39 million.
• Gilead reported $2.01 earnings per share for the last quarter, surpassing analyst estimates, with revenue of $7.08 billion, marking a 1.4% year-over-year increase.
• The company has announced a quarterly dividend of $0.79, representing a yield of 2.7%, to be paid on September 29th to shareholders recorded by September 15th.

Swedbank AB boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,118,632 shares of the biopharmaceutical company's stock after acquiring an additional 16,663 shares during the period. Swedbank AB owned about 0.17% of Gilead Sciences worth $237,393,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $215,000. Nuveen Asset Management LLC raised its position in Gilead Sciences by 16.2% during the fourth quarter. Nuveen Asset Management LLC now owns 5,208,321 shares of the biopharmaceutical company's stock worth $481,093,000 after acquiring an additional 724,493 shares during the last quarter. NorthRock Partners LLC raised its position in Gilead Sciences by 280.3% during the fourth quarter. NorthRock Partners LLC now owns 11,207 shares of the biopharmaceutical company's stock worth $1,035,000 after acquiring an additional 8,260 shares during the last quarter. Finally, Pathstone Holdings LLC raised its position in Gilead Sciences by 3.6% during the fourth quarter. Pathstone Holdings LLC now owns 104,725 shares of the biopharmaceutical company's stock worth $9,672,000 after acquiring an additional 3,677 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $117.86 on Friday. Gilead Sciences, Inc. has a 1 year low of $81.57 and a 1 year high of $121.83. The firm has a 50 day moving average price of $113.97 and a 200 day moving average price of $110.07. The company has a market cap of $146.24 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 0.78 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is presently 62.95%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,371,330 in the last ninety days. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GILD shares. UBS Group lifted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.